BIOMAT Database Logo BIOMAT Database Logo

Reduced renal toxicity and improved clinical tolerance of amphotericin B mixed with intralipid compared with conventional amphotericin B in neutropenic patients. 1992

P Moreau, and N Milpied, and N Fayette, and J F Ramée, and J L Harousseau
Department of Haematology, CHU Hôtel Dieu, Nantes, France.

The clinical use of amphotericin B is sometimes limited by nephrotoxicity. In a randomized prospective study, 32 patients treated for haematological malignancies received either amphotericin B in 5% dextrose (group A, 16 patients, 0.7-1 mg/kg/day), or amphotericin B mixed with Intralipid (group B, 16 patients, 0.7-1 mg/kg/day) during prolonged neutropenia. Renal dysfunction occurred in 9/16 patients in group A and 2/16 patients in group B (P < 0.05). Clinical tolerance was improved with a reduction of fever with chills in 12/16 patients in group A compared with 5/16 in group B (P < 0.05). Preparation of amphotericin B with Intralipid reduces nephrotoxicity, improves clinical tolerance, may allow an increase in the daily dose of amphotericin B, and be an alternative to liposomal-amphotericin B infusion.

UI MeSH Term Description Entries
D007668 Kidney Body organ that filters blood for the secretion of URINE and that regulates ion concentrations. Kidneys
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009181 Mycoses Diseases caused by FUNGI. Fungus Diseases,Fungal Diseases,Fungal Infections,Fungus Infections,Disease, Fungal,Disease, Fungus,Diseases, Fungal,Diseases, Fungus,Fungal Disease,Fungal Infection,Fungus Disease,Fungus Infection,Infection, Fungal,Infection, Fungus,Infections, Fungal,Infections, Fungus
D009503 Neutropenia A decrease in the number of NEUTROPHILS found in the blood. Neutropenias
D003404 Creatinine Creatinine Sulfate Salt,Krebiozen,Salt, Creatinine Sulfate,Sulfate Salt, Creatinine
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D004361 Drug Tolerance Progressive diminution of the susceptibility of a human or animal to the effects of a drug, resulting from its continued administration. It should be differentiated from DRUG RESISTANCE wherein an organism, disease, or tissue fails to respond to the intended effectiveness of a chemical or drug. It should also be differentiated from MAXIMUM TOLERATED DOSE and NO-OBSERVED-ADVERSE-EFFECT LEVEL. Drug Tolerances,Tolerance, Drug,Tolerances, Drug
D005217 Fat Emulsions, Intravenous Emulsions of fats or lipids used primarily in parenteral feeding. Intravenous Fat Emulsion,Intravenous Lipid Emulsion,Lipid Emulsions, Intravenous,Emulsion, Intravenous Fat,Emulsion, Intravenous Lipid,Emulsions, Intravenous Fat,Emulsions, Intravenous Lipid,Fat Emulsion, Intravenous,Intravenous Fat Emulsions,Intravenous Lipid Emulsions,Lipid Emulsion, Intravenous
D005260 Female Females

Related Publications

P Moreau, and N Milpied, and N Fayette, and J F Ramée, and J L Harousseau
Efficacy and tolerance of an amphotericin B lipid (Intralipid) emulsion in the treatment of candidaemia in neutropenic patients.
January 1993, The Journal of antimicrobial chemotherapy,
P Moreau, and N Milpied, and N Fayette, and J F Ramée, and J L Harousseau
Renal tolerance with the use of intralipid-amphotericin B in low-birth-weight neonates.
August 1997, American journal of perinatology,
P Moreau, and N Milpied, and N Fayette, and J F Ramée, and J L Harousseau
Liposomal amphotericin B versus conventional amphotericin B in the empirical treatment of persistently febrile neutropenic patients.
February 2002, The Journal of antimicrobial chemotherapy,
P Moreau, and N Milpied, and N Fayette, and J F Ramée, and J L Harousseau
Safety and toxicity of amphotericin B in glucose 5% or intralipid 20% in neutropenic patients with pneumonia or fever of unknown origin: randomised study.
August 1998, BMJ (Clinical research ed.),
P Moreau, and N Milpied, and N Fayette, and J F Ramée, and J L Harousseau
Pharmacoeconomic analysis of liposomal amphotericin B versus conventional amphotericin B in the empirical treatment of persistently febrile neutropenic patients.
June 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
P Moreau, and N Milpied, and N Fayette, and J F Ramée, and J L Harousseau
Preventing fungal infection in neutropenic patients with acute leukemia: fluconazole compared with oral amphotericin B.
June 1994, Annals of internal medicine,
P Moreau, and N Milpied, and N Fayette, and J F Ramée, and J L Harousseau
[Renal tolerance to amphotericin B].
February 2001, Presse medicale (Paris, France : 1983),
P Moreau, and N Milpied, and N Fayette, and J F Ramée, and J L Harousseau
Safety and efficacy of liposomal amphotericin B compared with conventional amphotericin B for induction therapy of histoplasmosis in patients with AIDS.
July 2002, Annals of internal medicine,
P Moreau, and N Milpied, and N Fayette, and J F Ramée, and J L Harousseau
In vitro renal toxicity and in vivo therapeutic efficacy in experimental murine cryptococcosis of amphotericin B (Fungizone) associated with Intralipid.
February 1994, Antimicrobial agents and chemotherapy,
P Moreau, and N Milpied, and N Fayette, and J F Ramée, and J L Harousseau
Cytokines in mice treated with amphotericin B-intralipid.
April 2004, Medical mycology,
Copied contents to your clipboard!